We are live on !
Find out more
First Manhattan Portfolio holdings
AUM
$39.2B
Turnover
13.59%
1-Year Est. Return
21.04%
This Fund
S&P 500
This Quarter Est. Return
+4.31%
1 Year Est. Return
+21.04%
3 Year Est. Return
+83.94%
5 Year Est. Return
+115.5%
10 Year Est. Return
+416.22%
AUM
$16.4B
AUM Growth
+$49.9M
(+0.3%)
Cap. Flow
-$355M
Cap. Flow % of AUM
Cap. Flow %
-2.16%
Top 10 Holdings %
Top 10 Hldgs %
43.8%
Holding
1,532
New
77
Increased
144
Reduced
521
Closed
96
Avg Time Held
2.7
years
Top 10 Avg Time Held
2.1
years
Top 20 Avg Time Held
2.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Coty
COTY
|
+$139M |
| 2 |
Teva Pharmaceutical Industries Limited
TEVA
|
+$38M |
| 3 |
GCP
GCP Applied Technologies Inc.
GCP
|
+$34.7M |
| 4 |
Sonida Senior Living
SNDA
|
+$25.5M |
| 5 |
Theravance Biopharma
TBPH
|
+$24.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$68M |
| 2 |
ConocoPhillips
COP
|
+$44.3M |
| 3 |
Charles Schwab
SCHW
|
+$35.7M |
| 4 |
Zimmer Biomet
ZBH
|
+$33.7M |
| 5 |
Berkshire Hathaway Class A
BRK.A
|
+$26.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 37.63% |
| 2 | Healthcare | 12.77% |
| 3 | Industrials | 9.66% |
| 4 | Technology | 8.73% |
| 5 | Consumer Staples | 6.71% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Berkshire Hathaway Class A
BRK.A
$1.16T
| $3.58B | 21.79% |
14,679
-115
| -0.8% | -$26.5M |
2013 Q2
14 quarters
|
|
2
Brookfield
BN
$84.8B
| $558M | 3.39% |
47,355,993
-1,315,409
| -3% | -$16M |
2013 Q2
14 quarters
|
|
3
Microsoft
MSFT
$3.89T
| $501M | 3.05% |
8,066,837
-26,134
| -0.3% | -$1.57M |
2013 Q2
14 quarters
|
|
4
Berkshire Hathaway Class B
BRK.B
$1.16T
| $452M | 2.75% |
2,774,579
-15,865
| -0.6% | -$2.44M |
2013 Q2
14 quarters
|
|
5
Apple
AAPL
$5.07T
| $433M | 2.63% |
14,962,404
-152,844
| -1% | -$4.33M |
2013 Q2
14 quarters
|
|
6
Johnson & Johnson
JNJ
$635B
| $298M | 1.81% |
2,588,309
-31,556
| -1% | -$3.65M |
2013 Q2
14 quarters
|
|
7
AB InBev
BUD
$166B
| $256M | 1.56% |
2,426,205
-62,109
| -2% | -$6.96M |
2013 Q2
14 quarters
|
|
8
Honeywell
HON
$70.1B
| $242M | 1.47% |
2,313,468
+2,866
| +0.1% | +$291K |
2013 Q2
14 quarters
|
|
9
Wells Fargo
WFC
$247B
| $237M | 1.44% |
4,306,341
-204,382
| -5% | -$10.3M |
2013 Q2
14 quarters
|
|
|
10
Zimmer Biomet
ZBH
$18.8B
| $233M | 1.42% |
2,327,493
-314,838
| -12% | -$33.7M |
2013 Q2
14 quarters
|
|
11
Danaher
DHR
$162B
| $227M | 1.38% |
3,283,227
-24,926
| -0.8% | -$1.73M |
2013 Q2
14 quarters
|
|
12
Comcast
CMCSA
$80.5B
| $218M | 1.32% |
6,306,154
-87,924
| -1% | -$2.94M |
2013 Q2
14 quarters
|
|
13
CVS Health
CVS
$120B
| $209M | 1.27% |
2,652,359
-153,095
| -5% | -$12.4M |
2013 Q2
14 quarters
|
|
14
Aramark
ARMK
$13.9B
| $193M | 1.18% |
7,495,563
-208,810
| -3% | -$5.46M |
2014 Q2
10 quarters
|
|
15
Gilead Sciences
GILD
$193B
| $192M | 1.17% |
2,683,990
+79,101
| +3% | +$5.88M |
2013 Q2
14 quarters
|
|
16
Pfizer
PFE
$171B
| $168M | 1.02% |
5,450,311
+616,271
| +13% | +$18.8M |
2013 Q2
14 quarters
|
|
17
Philip Morris
PM
$311B
| $155M | 0.94% |
1,697,697
-26,507
| -2% | -$2.46M |
2013 Q2
14 quarters
|
|
18
American International
AIG
$42.5B
| $138M | 0.84% |
2,115,141
-265,859
| -11% | -$16.7M |
2013 Q2
14 quarters
|
|
19
Newell Brands
NWL
$2.28B
| $137M | 0.83% |
3,059,015
+140,390
| +5% | +$6.79M |
2016 Q1
3 quarters
|
|
20
3M
MMM
$89.5B
| $132M | 0.8% |
883,580
-15,374
| -2% | -$2.22M |
2013 Q2
14 quarters
|
|
21
IBM
IBM
$240B
| $129M | 0.79% |
815,069
-29,782
| -4% | -$4.54M |
2013 Q2
14 quarters
|
|
22
Accenture
ACN
$153B
| $128M | 0.78% |
1,092,329
-49,587
| -4% | -$5.89M |
2013 Q2
14 quarters
|
|
23
Oracle
ORCL
$382B
| $126M | 0.76% |
3,266,517
+220,401
| +7% | +$8.62M |
2013 Q2
14 quarters
|
|
|
24
Coty
COTY
$2.84B
| $123M | 0.75% |
+6,723,666
| New | +$139M |
2016 Q4
0 quarters
|
|
25
GE Aerospace
GE
$296B
| $121M | 0.74% |
800,415
-12,254
| -2% | -$1.78M |
2013 Q2
14 quarters
|
|
Similar funds
First Manhattan's Q4 2016 Portfolio in Review
As of Q4 2016, First Manhattan held 1,532 positions worth $16.4B, up 0.3% from $16.4B the previous quarter. Its ten largest holdings account for 44% of the portfolio.
First Manhattan's Q4 2016 filing shows 77 new, 144 increased, 521 reduced and 96 closed positions. Its largest new stake was Coty: 6,723,666 shares worth $123M. The largest sale was Allergan plc, an estimated $68M.
By sector, the portfolio is most concentrated in Financials at 38% of assets, up from 35% a quarter earlier, followed by Healthcare and Industrials.
- First Manhattan's largest Q4 2016 buy was Coty: 6,723,666 shares worth $123M.
- First Manhattan added most to Teva Pharmaceutical Industries Limited in Q4 2016, an estimated $38M increase.
- First Manhattan's biggest Q4 2016 reduction was Allergan plc, cutting an estimated $68M.
- First Manhattan fully exited Starz - Series A in Q4 2016, selling an estimated $2.9M.
- First Manhattan's ten largest holdings make up 44% of its $16.4B portfolio in Q4 2016.
- First Manhattan opened 77 new positions and closed 96 in Q4 2016.
- First Manhattan's portfolio value rose 0.3% quarter-over-quarter to $16.4B.
Based on First Manhattan's 13F filing for Q4 2016, filed 25 Jan 2017.